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Strengths and limitations of this study
 ► This is a multicentre study, including five geograph-
ically diverse study sites.
 ► The study aims to overcome the main limitations of 
the current vision screening tools in childhood.
 ► The main strength is its potential to include a large 
sample of children with a wide range of features, 
not only in terms of visual disorders, but also social, 
ethnic and geographical characteristics.
 ► The main limitation lies in the number of ophthal-
mologists running the clinical protocol, which will 
be faced a with very exhaustive training programme 
and will receive detailed documentation describing 
the protocol.
AbStrACt
Introduction Around 70% to 80% of the 19 million visually 
disabled children in the world are due to a preventable or 
curable disease, if detected early enough. Vision screening 
in childhood is an evidence- based and cost- effective way 
to detect visual disorders. However, current screening 
programmes face several limitations: training required to 
perform them efficiently, lack of accurate screening tools 
and poor collaboration from young children.
Some of these limitations can be overcome by new 
digital tools. Implementing a system based on artificial 
intelligence systems avoid the challenge of interpreting 
visual outcomes.
The objective of the TrackAI Project is to develop a 
system to identify children with visual disorders. The 
system will have two main components: a novel visual 
test implemented in a digital device, DIVE (Device for an 
Integral Visual Examination); and artificial intelligence 
algorithms that will run on a smartphone to analyse 
automatically the visual data gathered by DIVE.
Methods and analysis This is a multicentre study, with 
at least five centres located in five geographically diverse 
study sites participating in the recruitment, covering 
Europe, USA and Asia.
The study will include children aged between 6 months 
and 14 years, both with normal or abnormal visual 
development.
The project will be divided in two consecutive phases: 
design and training of an artificial intelligence (AI) 
algorithm to identify visual problems, and system 
development and validation. The study protocol will 
consist of a comprehensive ophthalmological examination, 
performed by an experienced paediatric ophthalmologist, 
and an exam of the visual function using a DIVE.
For the first part of the study, diagnostic labels will be 
given to each DIVE exam to train the neural network. For 
the validation, diagnosis provided by ophthalmologists will 
be compared with AI system outcomes.
Ethics and dissemination The study will be conducted 
in accordance with the principles of Good Clinical Practice. 
This protocol was approved by the Clinical Research Ethics 
Committee of Aragón, CEICA, on January 2019 (Code 
PI18/346).
Results will be published in peer- reviewed journals and 
disseminated in scientific meetings.
trial registration number ISRCTN17316993.
IntroduCtIon
background
The WHO estimates 19 million children in 
the world with visual impairment. Reports 
of the global magnitude and causes of visual 
impairments confirm that 70% to 80% of all 
visual impairment are either preventable or 
curable, if detected in time.1–3
There is an important shortage of paedi-
atric ophthalmologists in the world to provide 
timely diagnosis. As a result, most of these 
children will remain undiagnosed for years, 
leading to consequences on their vision, 
general development, educational opportu-
nities, social life and prospects.4 However, it is 
especially critical in low- and middle- income 
countries (LMIC), where blind children face 
higher risk of death during childhood (60% 
of the children becoming blind in LMIC are 
thought to die during the first 2 years).5
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Childhood blindness is a priority of ‘Vision 2020 the 
Right to Sight’.6 Since the highest incidence of visual 
problems occurs during the first 5 years of life, early 
detection of any potential disorder causing abnormal 
visual development is a priority. All the tools currently 
available to assess visual function require active collabora-
tion from the patients and/or an experienced examiner. 
Incorporating an accurate and easy- to- use tool to identify 
children with abnormal visual development, as young as 
6 months of age, would become a major opportunity to 
prevent visual impairment in childhood.
The major causes of visual impairment in childhood 
differ from country to country. In low- income regions 
nutritional and infectious conditions are the main causes 
for blindness. In particular, vitamin A deficiency, corneal 
scarring related to measles or ophthalmia neonatorum 
are common in certain countries of Asia or sub- Saharan 
Africa. Retinopathy of prematurity is causing major visual 
impairment in middle- income countries. Nevertheless, 
the aetiologies of severe visual deficiencies in developed 
countries are mainly hereditary and perinatal factors.7
Uncorrected refractive errors are cause of less severe 
visual impairment, but it is currently affecting around 
12.8 million children aged from 5 to 15 years in the world, 
with the highest prevalence reported in urban areas of 
China and Southeast Asia.8 Increasing rates of myopia 
has become a concerning public health problem in wide 
regions.9 Finally, amblyopia is the result of different 
conditions, such as strabismus, uncorrected refractive 
errors or vision deprivation, that cause visual impairment, 
but avoidable if treated in time. It is considered an alter-
ation in the visual neural pathway in a child’s developing 
brain.10 Among children younger than 6 years, 1% to 4% 
present amblyopia or a condition which could lead to 
amblyopia if remains untreated.10 11 Therefore, screening 
for amblyopia is one of the most important goals in paedi-
atric ophthalmology programmes.
Study justification
Systematic evaluation of visual function is critical to detect 
visual impairment, its causes and to plan therapeutic 
interventions. Screening programmes vary between coun-
tries, with low agreement in timing, target population 
or methods.12 There is solid evidence supporting visual 
screening between 3 to 5 years, but a lack of data from 
controlled studies under 3 years is pointed out.13 However, 
there is indirect evidence for preschool screening, as the 
better likelihood of improving visual acuity as the sooner 
amblyopia treatment starts.14
Vision screening in childhood is usually done in primary 
care settings, with different rates of coverage, lower than 
50% among 3- year- old children and only 3% starting at 
age 6 months, even in developed countries.15 16 Children 
with abnormal findings in any screening programme 
should be referred for a complete eye examination, to 
confirm or rule out any visual disorder.
Current visual screening programmes face important 
limitations. As screening tools, clinical protocols should 
not be very time- consuming and must be, therefore, 
focussed on the most discriminative visual functions.17 
That is why they are mostly limited to visual acuity tests, 
ocular alignment, stereoacuity and red reflex test. For 
children younger than 3 years, visual acuity assessment is 
usually replaced by the fixation and follow test.18 When 
screening protocols include further assessments, such as 
monocular autorefractors, less than 50% of the children 
younger than 3 years are testable with current screening 
tools.19 However, all these assessments require training 
and experience not only to properly perform them but 
also to interpret their outcomes. It gives rise to with 
higher false- positive and false- negative rates the lower the 
experience of the examiner. Such are the limitations of 
current visual screening tools that most paediatricians 
report being unsatisfied with them, mainly because of 
inadequate training to run them and the time required 
for the exam.16
Instrument- based techniques, such as autorefractors, 
had demonstrated utility in visual screening programmes, 
especially as an alternative to eye charts for very young 
children or children with developmental delays,17 but 
their utility is limited to refractive errors and do not seem 
to decrease the barriers perceived by the examiners.16
Study motivation
During the last years, our research group has worked in the 
development of a new medical device to provide an auto-
mated, fast and accurate exploration of the visual func-
tion even in non- collaborative patients. DIVE (Devices 
for an Integral Visual Examination, developed by DIVE 
Medical Startup) has been specially designed to explore 
vision in children, including infants from 6 months of age 
and children with developmental issues. DIVE explores 
several aspects of the visual function by presenting care-
fully designed stimuli on a high- resolution screen while 
collecting accurate gaze data from the patient using eye 
tracking technology. Although running the tests does not 
require any especial training or expertise, interpreting 
their outcomes may be challenging for non- experienced 
examiners. Besides, analysing gaze data requires parame-
trised algorithms and heuristics that complicate the task 
of generic gaze data processing for all ages and visual 
pathologies.
Artificial intelligence (AI) provides a valuable assistance 
for the interpretation of multiple biological outcomes. AI 
tools have shown to reach and even exceed performance 
of expert humans in certain clinical tasks, such as iden-
tifying retinal diseases or recommending referral.20 We 
expect AI to overcome most of the existing limitations of 
vision screening in childhood. It avoids the challenge of 
interpreting the outcomes, dealing with the wide range 
of clinical variability of visual disorders, differences in 
normal performance depending on the age and unstable 
collaboration from young children.
Finally, digital devices can contribute to improve 
children’s collaboration by providing a child- friendly 
tool. Using this new approach, visual function could be 
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Figure 1 Proposed artificial intelligence framework, representing consecutive neural network training and validation phases. 
DIVE,Device for an Integral Visual Examination.
assessed in a quantitative and objective way, avoiding the 
lack of training personnel in certain areas, and improving 
quality of referrals.
HypotHESIS
Children with visual disorders can be identified from chil-
dren with a normally developed visual function using a 
trained neural network implemented in a DIVE.
objECtIvES
primary objectives
To develop a system based on artificial intelligence algo-
rithms to identify children with visual disorders, using a 
visual test implemented in a DIVE.
Secondary objectives
I. To describe visual development throughout child-
hood, from 6 months to 14 years of age.
II. To create normal reference databases for every age 
and visual test, assessing grating visual acuity, grating 
contrast sensitivity, colour perception and oculomo-
tor control.
III. To identify different patterns of visual function relat-
ed to the main causes of visual impairment in child-
hood in the world.
MEtHodS
Study design
The study will consist of two consecutive phases, presented 
in figure 1.
In the first one, we will design and train an AI neural 
network, including the following steps:
 ► Design of the visual exam to run in DIVE in order 
to collect binocular and monocular gaze data from 
oculomotor control, visual acuity, contrast sensi-
tivity and colour perception tests. This test is based 
on existing larger versions of visual tests already vali-
dated and normalised. Consecutive pilot studies will 
be carried out to confirm feasibility and validity of the 
final version of the visual test. This exam must provide 
all the required data in the shortest time possible. This 
visual exam will be implemented in DIVE to enable 
systematic gaze data collection and storage.
 ► Collection of monocular and binocular gaze data 
using DIVE, labelled by an experienced paediatric 
ophthalmologist as Normal visual function or Abnormal 
visual function. Those data sets labelled as Abnormal 
visual function will be also classified as Significant 
refractive error, Media opacity, Retinal disorder, Optic nerve 
disorder, Cerebral visual impairment, Strabismus or Other 
pathologies. Patients fulfilling the inclusion criteria 
will be recruited from at least five different paediatric 
ophthalmology units, from different countries.
 ► Design and development of the supervised neural 
network models. The neural network will take as an 
input the results obtained from the DIVE exam and 
the gaze data logs recorded while the patient was 
tested for oculomotor control, visual acuity, contrast 
sensitivity, colour perception and quality of the cali-
bration of the eye tracking system. These data will be 
available from both monocular and binocular exams, 
and will be completed with age and gender. The 
output of the neural network will be the probability 
for the patient to have normal or abnormal monoc-
ular and binocular visual function, and any of the 
pathologies listed in the previous paragraph.
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Figure 2 Steps of the study clinical protocol. DIVE,Device 
for an Integral Visual Examination.
During development, the AI algorithm will be trained 
providing the input and including the output as labels. 
Several options will be evaluated for the design of 
the neural network to process the gaze data log files, 
including long short- term memory (LSTM) layers and a 
series of convolutional layers. The output values will be 
concatenated and fed into fully connected layers in order 
to produce the final result.
 ► Training of the neural network models. Collected 
patient data will be used to train the neural network. 
Note that to generate the monocular diagnosis prob-
abilities, each eye of the patient will be considered 
independently, thus roughly doubling the amount of 
training data.
 ► First, the complete system to identify visual pathol-
ogies will be built. The system will be composed 
of a DIVE device and a Huawei P30 smartphone, 
which will communicate via Bluetooth. The doctor 
will use the smartphone to control gaze data collec-
tion, which will happen through the DIVE device, 
thus reducing the doctor’s interference in the visual 
exam. At the end of the exam, the collected data will 
run through the trained neural network to produce 
the probability for the patient to have normal or 
abnormal visual development, and the pathologies 
listed above.
 ► Second, the diagnostic accuracy of the system will be 
compared with the diagnosis provided by paediatric 
ophthalmologists.
In the second phase, we will construct and validate the 
system, with the following steps:
 ► First, the complete system to identify visual pathol-
ogies will be built. The system will be composed 
of a DIVE device and a Huawei P30 smartphone, 
which will communicate via Bluetooth. The doctor 
will use the smartphone to control gaze data collec-
tion, which will happen through the DIVE device, 
thus reducing the doctor’s interference in the visual 
exam. At the end of the exam, the collected data will 
run through the trained neural network to produce 
the probability for the patient to have normal or 
abnormal visual development, and the pathologies 
listed above.
 ► Second, the diagnostic accuracy of the system will be 
compared with the diagnosis provided by paediatric 
ophthalmologists.
Study setting
This study will be coordinated by the Vision, Image and 
Neurodevelopment Research Group, from the Instituto 
de Investigacion Sanitaria de Aragon (IIS Aragon), in 
Zaragoza, Spain. The recruitment of participants will be 
conducted in at least five geographically diverse study 
sites, covering Europe, Asia and USA.
Study protocol
The study protocol will consist of the following steps, as 
presented in figure 2:
1. Comprehensive ophthalmological examination, per-
formed by an experienced paediatric ophthalmologist, 
including:
 – Oculomotor control, including fixation, smooth 
pursuit and saccadic performance;
 – Monocular uncorrected visual acuity at 3 m, tai-
lored to the child’s age and level of cooperation, us-
ing LEA grating test from 6 months to 2 years, LEA 
symbols chart from 2 to 4 years and Early Treatment 
Diabetic Retinopathy Study (ETDRS) visual acuity 
chart over 5 years of age;
 – Monocular uncorrected visual acuity at 65 cm with a 
LEA symbols near vision card;
 – Ocular alignment, using Hirschberg test or cover 
test for children younger or older than 3 years re-
spectively;
 – Ocular motility, including ductions and versions;
 – Stereopsis evaluation, with Titmus stereotest;
 – Red reflex test;
 – Ocular examination, by ocular inspection or slit 
lamp exam.
2. DIVE exam, which will be run by an optometrist.
3. Funduscopy, refraction under cycloplegia and best- 
corrected visual acuity.
Equipment
For this study, a DIVE will be used. It includes a 12- inch 
screen, corresponding to a visual angle of 22.11 degrees 
horizontally and 14.81 degrees vertically, assisted by eye 
tracking, with a maximum temporal resolution of 120 Hz. 
A child- friendly digital test has been specifically designed 
for TrackAI Project. It includes carefully designed and 
validated visual stimuli, to assess oculomotor control, 
visual acuity, contrast sensitivity and colour perception, 
both monocularly and binocularly.
DIVE exam will be performed in a quiet room under 
mesopic ambient illumination. Children will be posi-
tioned on a chair at approximately 65 cm from the screen 
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and asked to fixate on the different stimuli on the screen, 
trying not to move their heads.
Before starting the exam, DIVE shows on the screen a 
drawing of the eyes of the patient as they are captured 
by the eye tracker, and two ovals that represent the ideal 
position and size the eyes should have on the screen and 
must be used as a guideline. To ensure the child is posi-
tioned at the optimal relative height and distance from 
the screen, the patient and the DIVE must be adjusted so 
that the drawing of the eyes matches the oval guidelines 
as close as possible both in position and size.
Children will have no head immobilisation and the 
same instructions will be given to all of the included 
participants by an animated picture of a child speaking in 
their native language. Children younger than 24 months 
will be positioned on a parent’s lap, and instructions will 
be given to them to keep their heads steady.
DIVE exam will be performed without any optical 
correction, due to the methodology and goals of the 
study. Children wearing glasses will be asked to remove 
them at least 30 min before running the test, to simulate 
a patient with no previous optical correction.
The calibration procedure of the eye tracker (ET) will 
always be performed prior to test. Each child will be asked 
to fixate on a picture of an animal with associated sound, 
appearing at nine different locations across the screen, 
one at a time. The calibration procedure will be repeated 
until a good calibration has been reached, based on 
manufacturer’s recommendations. Children unable to 
achieve an acceptable calibration after three attempts 
will proceed with the test, since this is mostly due to poor 
visual function.
ElIgIbIlIty CrItErIA
Inclusion criteria
I. Age between 6 months and 14 years.
II. Visual fixation stable enough to allow attentive fixa-
tion on the Lang cube.
III. Assessments performed for all the following visual 
outcomes (although in some cases information may 
not be obtained): oculomotor control, ocular exam-
ination, visual acuity, ocular motility, red reflex, re-
fraction under cycloplegia and funduscopy.
IV. Informed consent signed by parents or guardians 
of the child, and assent by children older than 12 
years of age (included as online supplementary file 
1).
Exclusion criteria
I. Previous ocular, muscular or orbital surgery.
II. Bad general health state, which does not allow an 
examination with DIVE.
Children previously treated with optical correction, 
minor topic treatments or any therapy for amblyopia, will 
not be excluded.
vArIAblES
1. Demographic information:
 ► date of birth
 ► date of assessment
 ► gender
 ► gestational age at birth
 ► birth weight
 ► perinatal adverse events
 ► medical diseases
 ► treatments
 ► ethnicity
 ► eye colour
II. Ophthalmic history:
 ► amblyopia
 ► patching
 ► current optical correction
 ► others
III. Monocular visual assessment:
 ► visual fixation: quality, location and duration
 ► smooth pursuit
 ► saccadic performance: saccadic reaction time and 
accuracy
 ► visual acuity, assessed with different optotypes 
depending on the age
 ► stereoacuity
 ► ocular alignment and ocular motility
 ► binocular red reflex
 ► anterior segment exam
 ► refraction under cycloplegia
 ► ophthalmoscopy
IV. Gaze positions throughout all DIVE test.
outCoMES
Outcomes related to the AI algorithm during the valida-
tion phase were:
 ► True positives (TP)
 ► True negatives (TN)
 ► False positives (FP)
 ► False negatives (FN)
 ► Sensitivity=TP/(TP +FN)
 ► Specificity=TN/(TN +FP)
 ► Accuracy=(TP+TN)/(TP+TN+FP+FN)
 ► Area under the receiver operating characteristic curve 
(AUC)
They will be measured after the finalisation of the clin-
ical part with the final database.
pArtICIpAnt tIMElInE
All the participants will be enrolled from March 2019 to 
December 2019.
SAMplE SIzE
For the training of the AI system, a minimum of 2000 
patients will be recruited. We expect at least 40% of them 
to have normal visual development and at least 5% to be 
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in each classification group with abnormal visual devel-
opment. Since eyes will be used independently for the 
monocular examination, at least 4000 records will be avail-
able for training that part of the system. However, sample 
size will be adjusted along the recruitment, based on 
the classification performance of the model. Estimating 
sample size required to train a deep learning model is 
considered an impossible task, since it depends on many 
different aspects, which are unavailable at the beginning 
of the recruitment, such as the statistical features of the 
data.
For the validation phase, we will include a minimum of 
200 patients from different age groups, with both normal 
visual development and a variety of visual pathologies.
dAtA CollECtIon
Participants will be recruited in at least five different 
hospitals. All the information from every patient will be 
collected in a database allocated in the DIVE devices.
Each participant will be given a code, which will be the 
only link between demographic information, visual assess-
ment and visual examination with DIVE. Anonymised 
data sets of visual outcomes and demographic informa-
tion, labelled by the ophthalmologists, will be automati-
cally uploaded to a non- publically available repository in 
Google Cloud Storage, through which the Coordinating 
Unit will have instant access to the data.
All the information gathered will be treated according 
to the current regulations of personal data protection. 
All the parents or guardians from the patients will sign 
a written informed consent, and everyone in charge of 
handling the data will sign an non- disclosure agreement 
(NDA).
dAtA MonItorIng
Before collected data is used to train the neural network, 
it will go through a thorough auditing stage. This data 
auditing stage is designed to guarantee that the protocol 
is being followed consistently and that all collected 
data is free of errors. It consists of an automatic analysis 
performed with custom Python code, manual revision of 
automatically detected potential issues in collected data 
and manual random revision of patient data from every 
recruitment centre.
During this stage, will also compute statistics on the 
collected data to have real- time information on the number 
of recruited patients, predominant age groups, detected 
visual pathologies and quality of the collected data. This 
information is used to guide the recruitment process in 
order to obtain a balanced and varied data set.
pAtIEnt And publIC InvolvEMEnt
Patients were not involved in any part of the design of the 
study.
StAtIStICAl AnAlySIS
Study success will be predefined based on sensitivity, spec-
ificity and AUC outcomes of the AI system during the vali-
dation phase. Sensitivity ranges from 0.6 to 0.9 in most of 
the vision screening programmes aiming to detect ambly-
opia risk factors, using a combination of clinical tests (ie, 
visual acuity, stereoacuity and ocular alignment), with 
specificity ranging from 0.86 to 0.94.21 However, most 
of the studies have been performed on children aged 
at least 3 years. Screening programmes based on digital 
devices, such as autorefractometers, have shown slightly 
lower accuracy, with sensitivity of 0.88 and specificity of 
0.58 for children aged 3 to 5 years, and 0.80 and 0.41, 
respectively, for children younger than 3 years.19
The hypotheses of interest will be:
H0: p<p0 and HA: p≥p0, where p is the sensitivity or 
specificity of the AI system. For children older than 3 
years, p0 will be set at 0.90 for sensitivity and 0.70 for spec-
ificity, and for children younger than 3 years, p0 will be 
0.85 and 0.50, respectively.
One- sided testing will be used, with a 2.5% Type I error.
Values of AUC will be used to assess the overall diag-
nostic accuracy of the AI algorithm. Outcomes, ranging 
from 0 to 1, will be interpreted using well- established deci-
sion thresholds: An AUC lower or equal to 0.5 suggests 
no discrimination, 0.5 to 0.7 is considered low discrimina-
tion, 0.7 to 0.8 acceptable, 0.8 to 0.9 excellent and more 
than 0.9 is considered outstanding.22
Secondary objectives will be analysed by descriptive 
outcomes (ie, mean, SD, 95% CIs and z- scores) and 
normal distribution plots. Continuous variables will be 
compared using Student’s t- test or Mann- Whitney U test 
for non- normal distribution (Shapiro- Wilk’s test, p<0.05), 
and categorical variables by means of Pearson’s or Fish-
er’s exact tests. Multivariate analysis will be done using 
linear or logistic regression models.
EtHICS And dISSEMInAtIon
The study will be conducted in accordance with the prin-
ciples of Good Clinical Practice. All the study has been 
designed following the ethical principles of the Declara-
tion of Helsinki from 1964, reviewed by the WHO later in 
2000 and the Spanish Data Protection Act (Organic Law 
3/2018).
Patient data will be anonymised, that is, personal infor-
mation from patients will not be included in the data set.
Results will be published in peer- reviewed journals and 
disseminated at international scientific meetings.
dISCuSSIon
Vision screening in childhood is a cost- effective way to 
detect visual disorders and has been recommended for 
children of all ages by most Paediatric Ophthalmology 
scientific institutions.17 However, examiners in charge of 
it face important barriers, including limited training to 
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perform it efficiently, lack of accurate screening tools and 
poor collaboration from children younger than 3 years.16
With this project, we aim to develop an easy- to- use 
system to perform a fast vision screening in children 
from 6 months of age. The system will include artificial 
intelligence algorithms to overcome the difficulties of 
interpreting the outcomes of a comprehensive visual 
assessment.
The main strength of this study lies in the large sample 
of children involved and its potential to include a hetero-
geneous sample of participants, in terms of age, ethnicity, 
cultural background and geographical location. It will 
ensure the external validity of the trained neural networks 
in any different setting. The main limitation is related 
to the number of ophthalmologists recruiting children 
and running the clinical protocol. In order to avoid this 
source of bias, the Coordinating Unit will provide all the 
researchers with very exhaustive training programme and 
documentation.
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